MedDataX Logo

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

NCT ID: NCT02554890

Last Updated: 2021-01-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

887 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-29

Study Completion Date

2018-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

NCT04113109

Heart Failure
COMPLETED PHASE4

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742

Heart Failure With Preserved Ejection Fraction Chronic Kidney Diseases
ENROLLING_BY_INVITATION PHASE1/PHASE2

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

NCT03005184

Heart Failure NYHA Class I Heart Failure NYHA Class II Heart Failure NYHA Class III
WITHDRAWN PHASE2

The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

NCT04572724

Peritoneal Dialysis Complication Hemodialysis Complication Heart Failure
UNKNOWN PHASE4

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

NCT05498181

Hemodialysis
RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sacubitril/valsartan (LCZ696)

Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.

Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack).

Group Type EXPERIMENTAL

sacubitril/valsartan (LCZ696)

Intervention Type DRUG

sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

enalapril matching placebo

Intervention Type DRUG

enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.

Enalapril

Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.

Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)

Group Type ACTIVE_COMPARATOR

Enalapril

Intervention Type DRUG

Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.

sacubitril/valsartan (LCZ696) matching placebo

Intervention Type DRUG

matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sacubitril/valsartan (LCZ696)

sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

Intervention Type DRUG

Enalapril

Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.

Intervention Type DRUG

sacubitril/valsartan (LCZ696) matching placebo

matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

Intervention Type DRUG

enalapril matching placebo

enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LCZ696

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Possess the capacity to provide written informed consent which must be obtained before any assessment is performed.
2. Currently hospitalized for ADHF. Patients with a diagnosis of acute heart failure had to have symptoms and signs of fluid overload (i.e. jugular venous distention, edema or rales on auscultation or pulmonary congestion on chest x-ray) at time of hospitalization.
3. Eligible patients will be randomized no earlier than 24 hours and up to ten days after presentation while still hospitalized as long as meet the following definition of stable status:

* SBP ≥100mm Hg for the preceding 6 hours prior to randomization; no symptomatic hypotension
* No increase (intensification) in i.v. diuretic dose within last 6 hours prior to randomization
* No i.v. inotropic drugs for 24 hours prior to randomization
* No i.v. vasodilators including nitrates within last 6 hours prior to randomization
4. LVEF ≤40% within the past 6 months (including current hospitalization) using echocardiography, multi gated acquisition scan (MUGA), CT scanning, MRI or ventricular angiography, provided no subsequent study documented an EF of \>40%.
5. Elevated NT-proBNP ≥ 1600pg/mL OR BNP ≥400 pg/mL during current hospitalization.

Exclusion Criteria

1. Currently taking sacubitril/valsartan tablets or any use within the past 30 days.
2. Enrollment in any other clinical trial involving an investigational agent or investigational device.
3. History of hypersensitivity, known or suspected contraindications, or intolerance to any of the study drugs, including ACEIs, ARBs, or Sacubitril (NEP inhibitor).
4. Patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy.
5. Requirement of treatment with both ACE inhibitor and ARB.
6. eGFR \< 30 ml/min/1.73 m2 as measured by the simplified Modification of Diet in Renal Disease (MDRD) formula at screening.
7. Serum potassium \> 5.2 mEq/L at screening.
8. Known hepatic impairment (as evidenced by total bilirubin \> 3 mg/dL, or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as varices
9. Acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid or other major CV surgery; percutaneous coronary intervention (PCI) or carotid angioplasty, within one month prior to Visit 1.
10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
11. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Birmingham, Alabama, United States

Site Status

Novartis Investigative Site

Fort Smith, Arkansas, United States

Site Status

Novartis Investigative Site

Little Rock, Arkansas, United States

Site Status

Novartis Investigative Site

Bakersfield, California, United States

Site Status

Novartis Investigative Site

Fresno, California, United States

Site Status

Novartis Investigative Site

Long Beach, California, United States

Site Status

Novartis Investigative Site

Los Angeles, California, United States

Site Status

Novartis Investigative Site

Los Angeles, California, United States

Site Status

Novartis Investigative Site

Orange, California, United States

Site Status

Novartis Investigative Site

Pasadena, California, United States

Site Status

Novartis Investigative Site

Sacramento, California, United States

Site Status

Novartis Investigative Site

San Diego, California, United States

Site Status

Novartis Investigative Site

San Marino, California, United States

Site Status

Novartis Investigative Site

San Pablo, California, United States

Site Status

Novartis Investigative Site

Stanford, California, United States

Site Status

Novartis Investigative Site

Denver, Colorado, United States

Site Status

Novartis Investigative Site

Littleton, Colorado, United States

Site Status

Novartis Investigative Site

Bridgeport, Connecticut, United States

Site Status

Novartis Investigative Site

Hartford, Connecticut, United States

Site Status

Novartis Investigative Site

Hartford, Connecticut, United States

Site Status

Novartis Investigative Site

West Haven, Connecticut, United States

Site Status

Novartis Investigative Site

Washington D.C., District of Columbia, United States

Site Status

Novartis Investigative Site

Atlantis, Florida, United States

Site Status

Novartis Investigative Site

Daytona Beach, Florida, United States

Site Status

Novartis Investigative Site

Fort Lauderdale, Florida, United States

Site Status

Novartis Investigative Site

Gainesville, Florida, United States

Site Status

Novartis Investigative Site

Gainesville, Florida, United States

Site Status

Novartis Investigative Site

Hollywood, Florida, United States

Site Status

Novartis Investigative Site

Jacksonville, Florida, United States

Site Status

Novartis Investigative Site

Jacksonville, Florida, United States

Site Status

Novartis Investigative Site

Lakeland, Florida, United States

Site Status

Novartis Investigative Site

Sarasota, Florida, United States

Site Status

Novartis Investigative Site

Tampa, Florida, United States

Site Status

Novartis Investigative Site

Tampa, Florida, United States

Site Status

Novartis Investigative Site

Vero Beach, Florida, United States

Site Status

Novartis Investigative Site

Winter Haven, Florida, United States

Site Status

Novartis Investigative Site

Augusta, Georgia, United States

Site Status

Novartis Investigative Site

Macon, Georgia, United States

Site Status

Novartis Investigative Site

Marietta, Georgia, United States

Site Status

Novartis Investigative Site

Boise, Idaho, United States

Site Status

Novartis Investigative Site

Aurora, Illinois, United States

Site Status

Novartis Investigative Site

Elk Grove Village, Illinois, United States

Site Status

Novartis Investigative Site

Oakbrook Terrace, Illinois, United States

Site Status

Novartis Investigative Site

Park Ridge, Illinois, United States

Site Status

Novartis Investigative Site

Peoria, Illinois, United States

Site Status

Novartis Investigative Site

Peoria, Illinois, United States

Site Status

Novartis Investigative Site

Winfield, Illinois, United States

Site Status

Novartis Investigative Site

Elkhart, Indiana, United States

Site Status

Novartis Investigative Site

Indianapolis, Indiana, United States

Site Status

Novartis Investigative Site

Indianapolis, Indiana, United States

Site Status

Novartis Investigative Site

Muncie, Indiana, United States

Site Status

Novartis Investigative Site

Richmond, Indiana, United States

Site Status

Novartis Investigative Site

Des Moines, Iowa, United States

Site Status

Novartis Investigative Site

Kansas City, Kansas, United States

Site Status

Novartis Investigative Site

Louisville, Kentucky, United States

Site Status

Novartis Investigative Site

Louisville, Kentucky, United States

Site Status

Novartis Investigative Site

Alexandria, Louisiana, United States

Site Status

Novartis Investigative Site

Baton Rouge, Louisiana, United States

Site Status

Novartis Investigative Site

Slidell, Louisiana, United States

Site Status

Novartis Investigative Site

Bangor, Maine, United States

Site Status

Novartis Investigative Site

Annapolis, Maryland, United States

Site Status

Novartis Investigative Site

Baltimore, Maryland, United States

Site Status

Novartis Investigative Site

Boston, Massachusetts, United States

Site Status

Novartis Investigative Site

Boston, Massachusetts, United States

Site Status

Novartis Investigative Site

Ann Arbor, Michigan, United States

Site Status

Novartis Investigative Site

Bay City, Michigan, United States

Site Status

Novartis Investigative Site

Detroit, Michigan, United States

Site Status

Novartis Investigative Site

Maplewood, Minnesota, United States

Site Status

Novartis Investigative Site

Minneapolis, Minnesota, United States

Site Status

Novartis Investigative Site

Saint Paul, Minnesota, United States

Site Status

Novartis Investigative Site

Saint Paul, Minnesota, United States

Site Status

Novartis Investigative Site

Hattiesburg, Mississippi, United States

Site Status

Novartis Investigative Site

Jackson, Mississippi, United States

Site Status

Novartis Investigative Site

Kansas City, Missouri, United States

Site Status

Novartis Investigative Site

Omaha, Nebraska, United States

Site Status

Novartis Investigative Site

Reno, Nevada, United States

Site Status

Novartis Investigative Site

Camden, New Jersey, United States

Site Status

Novartis Investigative Site

Elmer, New Jersey, United States

Site Status

Novartis Investigative Site

Haddon Heights, New Jersey, United States

Site Status

Novartis Investigative Site

Newark, New Jersey, United States

Site Status

Novartis Investigative Site

Brooklyn, New York, United States

Site Status

Novartis Investigative Site

Buffalo, New York, United States

Site Status

Novartis Investigative Site

Johnson City, New York, United States

Site Status

Novartis Investigative Site

Manhasset, New York, United States

Site Status

Novartis Investigative Site

New York, New York, United States

Site Status

Novartis Investigative Site

New York, New York, United States

Site Status

Novartis Investigative Site

New York, New York, United States

Site Status

Novartis Investigative Site

Poughkeepsie, New York, United States

Site Status

Novartis Investigative Site

Rochester, New York, United States

Site Status

Novartis Investigative Site

Staten Island, New York, United States

Site Status

Novartis Investigative Site

The Bronx, New York, United States

Site Status

Novartis Investigative Site

The Bronx, New York, United States

Site Status

Novartis Investigative Site

Chapel Hill, North Carolina, United States

Site Status

Novartis Investigative Site

Greenville, North Carolina, United States

Site Status

Novartis Investigative Site

Winston-Salem, North Carolina, United States

Site Status

Novartis Investigative Site

Grand Forks, North Dakota, United States

Site Status

Novartis Investigative Site

Cincinnati, Ohio, United States

Site Status

Novartis Investigative Site

Toledo, Ohio, United States

Site Status

Novartis Investigative Site

Oklahoma City, Oklahoma, United States

Site Status

Novartis Investigative Site

Tulsa, Oklahoma, United States

Site Status

Novartis Investigative Site

Abington, Pennsylvania, United States

Site Status

Novartis Investigative Site

Camp Hill, Pennsylvania, United States

Site Status

Novartis Investigative Site

Natrona Heights, Pennsylvania, United States

Site Status

Novartis Investigative Site

Philadelphia, Pennsylvania, United States

Site Status

Novartis Investigative Site

Providence, Rhode Island, United States

Site Status

Novartis Investigative Site

Charleston, South Carolina, United States

Site Status

Novartis Investigative Site

Greenville, South Carolina, United States

Site Status

Novartis Investigative Site

Rapid City, South Dakota, United States

Site Status

Novartis Investigative Site

Nashville, Tennessee, United States

Site Status

Novartis Investigative Site

Nashville, Tennessee, United States

Site Status

Novartis Investigative Site

Dallas, Texas, United States

Site Status

Novartis Investigative Site

Dallas, Texas, United States

Site Status

Novartis Investigative Site

Houston, Texas, United States

Site Status

Novartis Investigative Site

Plano, Texas, United States

Site Status

Novartis Investigative Site

San Antonio, Texas, United States

Site Status

Novartis Investigative Site

White River Junction, Vermont, United States

Site Status

Novartis Investigative Site

Charlottesville, Virginia, United States

Site Status

Novartis Investigative Site

Lynchburg, Virginia, United States

Site Status

Novartis Investigative Site

Richmond, Virginia, United States

Site Status

Novartis Investigative Site

Virginia Beach, Virginia, United States

Site Status

Novartis Investigative Site

Clarksburg, West Virginia, United States

Site Status

Novartis Investigative Site

Madison, Wisconsin, United States

Site Status

Novartis Investigative Site

Wausau, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 Apr;198:145-151. doi: 10.1016/j.ahj.2018.01.004. Epub 2018 Jan 10.

Reference Type BACKGROUND
PMID: 29653636 (View on PubMed)

Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.

Reference Type BACKGROUND
PMID: 30415601 (View on PubMed)

Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation. 2019 May 7;139(19):2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331. No abstract available.

Reference Type BACKGROUND
PMID: 30955360 (View on PubMed)

Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019 Oct 21;40(40):3345-3352. doi: 10.1093/eurheartj/ehz240.

Reference Type BACKGROUND
PMID: 31093657 (View on PubMed)

Berardi C, Braunwald E, Morrow DA, Mulder HS, Duffy CI, O'Brien TX, Ambrosy AP, Chakraborty H, Velazquez EJ, DeVore AD; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 Oct;8(10):859-866. doi: 10.1016/j.jchf.2020.06.019. Epub 2020 Sep 9.

Reference Type DERIVED
PMID: 32919915 (View on PubMed)

Ambrosy AP, Braunwald E, Morrow DA, DeVore AD, McCague K, Meng X, Duffy CI, Rocha R, Velazquez EJ; PIONEER-HF Investigators. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 Sep 1;76(9):1034-1048. doi: 10.1016/j.jacc.2020.06.073.

Reference Type DERIVED
PMID: 32854838 (View on PubMed)

Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail. 2020 Oct;8(10):834-843. doi: 10.1016/j.jchf.2020.06.008. Epub 2020 Aug 12.

Reference Type DERIVED
PMID: 32800511 (View on PubMed)

DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ; PIONEER-HF Investigators. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 Feb 1;5(2):202-207. doi: 10.1001/jamacardio.2019.4665.

Reference Type DERIVED
PMID: 31825471 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=338

A Plain Language Trial Summary is available on novartisclinicatrials.com

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLCZ696BUS01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril/Valsartan
NCT06149806 RECRUITING
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
NCT00071331 COMPLETED PHASE3
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
NCT03128528 COMPLETED PHASE2
Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure
NCT03771729 UNKNOWN EARLY_PHASE1
ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE
NCT01290146 TERMINATED PHASE3
Losartan in Decompensated Heart Failure
NCT01857999 COMPLETED PHASE4
Role of ARNi in Ventricular Remodeling in Hypertensive LVH
NCT03553810 COMPLETED PHASE2
The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors
NCT02623036 UNKNOWN PHASE1
Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
NCT01584557 COMPLETED PHASE3
A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
NCT03984591 ENROLLING_BY_INVITATION PHASE4
Empagliflozin in Patients With Cirrhosis and Ascites
NCT05726032 RECRUITING PHASE2
Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure
NCT00843154 TERMINATED PHASE3
Hypertension in Hemodialysis Patients (Aim 3)
NCT00582114 TERMINATED PHASE3
Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function
NCT00568009 TERMINATED
A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
NCT06506994 COMPLETED PHASE1
Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
NCT00405639 COMPLETED PHASE1/PHASE2
Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion
NCT00806910 WITHDRAWN PHASE4
International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia
NCT00876876 WITHDRAWN PHASE3
SGLT2 Inhibitors in Glomerular Hyperfiltration
NCT04143581 WITHDRAWN PHASE2
Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
NCT00811486 WITHDRAWN NA
Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.
NCT00405548 COMPLETED PHASE1/PHASE2
Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure
NCT02606253 COMPLETED PHASE4
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
NCT00732771 COMPLETED PHASE2
Empagliflozin in Acute Heart Failure
NCT05305495 RECRUITING PHASE4
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
NCT00775840 COMPLETED PHASE3